Previous 10 | Next 10 |
Athersys (NASDAQ:ATHX) is scheduled to announce FY earnings results on Tuesday, March 15th, after market close. The consensus EPS Estimate is -$0.08 (+27.3% Y/Y) and the consensus Revenue Estimate is $7.5M (+490.6% Y/Y). For further details see: Athersys FY 2021 Earnings Preview
New CEO, Daniel A. Camardo, and Management to Host Conference Call on March 15, 2022 Athersys, Inc. (Nasdaq: ATHX) will release its fourth quarter and full year 2021 financial results on Tuesday, March 15, 2022, after the close of the U.S. financial markets. Athersys’...
AAP, ACTG, AESE, OTCPK:AOIFF, DADAASTS, ATHX, AXON, AYTU, BIOC, BITF, CIDM, CMP, OTCQX:CWBHF, CWBR, CWCO, CYBN, DM, DNMR, DRIO, OTCQB:ELTP, ETON, EVFM, GLAD, GNLN, GOEV, IBIO, IDEX, INPX, IONQ, ISUN, LCID, LUNA, MARK, OTCQX:MRMD, MVST, NDRA, NEPT, PLBY, POWW, PRCH, PRPO, QFIN, RKDA,...
Penny stocks are some of the highest-risk assets in the stock market today. But with that risk comes plenty of rewards and big rewards at that. In a given day, cheap stocks can explode hundreds of percentage points resulting in massive windfalls for traders. But if you’re new to thes...
Company to cover upcoming milestones, clinical programs and outlook Webcast scheduled for Wednesday, February 2, at 10:00 a.m. EST Athersys, Inc. (Nasdaq: ATHX), an international, clinical late-stage regenerative medicine company developing MultiStem ®...
Palm Beach, FL – January 5, 2022 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is the most common reason of progressive dementia in the elderly population. There has been an exponential rise in the number of cases of Alzheimer...
Athersys (NASDAQ:ATHX) has added ~19.6% in the pre-market on above-average volume after the company announced the peer-reviewed publication of results from a placebo-controlled study for its MultiStem cell therapy in patients with acute respiratory distress syndrome (ARDS). Conducte...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investor! We’re starting off Tuesday with a breakdown of the biggest pre-market stock movers! Source: f11photo/Shutterstock.com News from the FDA, earnings reports, Omicron concerns, and more ar...
Results show therapy was well-tolerated and support potential benefits in mortality, ventilator-free days, ICU-free days and quality of life outcomes Separately, data pooled from two independent studies provide further evidence of potential clinically meaningful benefit of Mul...
I covered Athersys' ischemic stroke trial earlier. The stock has fallen as a result of issues with this trial. However, Covid-induced ARDS is its most important indication, where it has market-leading positive data. For further details see: Athersys: COVID-ARDS Is The Co...
News, Short Squeeze, Breakout and More Instantly...
Athersys, Inc. (OTC: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update. Third Quarter 2023 and...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Athersys, Inc. (Nasdaq: ATHX), (“Athersys” or the “Company”) a cell therapy and regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to ra...